ETFs with BMRN as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|5.34%||First Trust Amex Biotechnology Index Fund (FBT)||+7.81 (15.81%)|
|5.29%||PowerShares Dynamic Biotech &Genome (PBE)||+1.82 (7.60%)|
|3.19%||iShares NASDAQ Biotechnology Index Fund (IBB)||+31.86 (22.02%)|
|2.85%||SPDR Series Trust SPDR S&P Biotech ETF (XBI)||+15.12 (17.55%)|
|2.41%||First Trust Health Care AlphaDEX (FXH)||+5.24 (14.80%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. We select product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. Our product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Naglazyme received marketing approval in the United States (U.S.) in May 2005, in the European Union (EU) in January 2006 and subsequently in other countries. Kuvan was granted marketing approval in the U.S. and EU in December 2007 and December 2008, respectively. ... More ...